Journal of Renal Nutrition
Volume 19, Issue 6 , Pages 443-449 , November 2009

Effect of Over-the-Counter Fish-Oil Administration on Plasma Lp(a) Levels in an End-Stage Renal Disease Population

  • Kristen M. Beavers, MPH, RD

      Affiliations

    • Center for Exercise, Nutrition, and Preventive Health Research, Department of Health, Human Performance, and Recreation, School of Education, Baylor University, Waco, Texas
    • ,
  • Daniel P. Beavers, MS

      Affiliations

    • Department of Statistics, Baylor University, Waco, Texas
    • ,
  • Rodney G. Bowden, PhD

      Affiliations

    • Center for Exercise, Nutrition, and Preventive Health Research, Department of Health, Human Performance, and Recreation, School of Education, Baylor University, Waco, Texas
    • Corresponding Author InformationAddress reprint requests to Rodney G. Bowden, PhD, Department of Health, Human Performance, and Recreation, School of Education, Baylor University, One Bear Place, #97304, Waco, TX 76798-7313.
    • ,
  • Ronald L. Wilson, MD

      Affiliations

    • Central Texas Nephrology Associates, Waco, Texas
    • ,
  • Mindy Gentile, MS, RD, LD

      Affiliations

    • Genzyne Corporation, San Antonio, Texas

References 

  1. Excerpts from the United States renal data system 1998 annual data report. Am J Kidney Dis. 1998;32(Suppl):S1–S162
  2. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13:1918–1927
  3. Shoji T, Kimoto E, Yamada A, et al. Elevated plasma free apo(a) levels in hemodialysis patients. Nephron. 2000;83:389–390
  4. Rhoads GG, Dahlen G, Berg K, et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540–2544
  5. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 1994;90:1688–1695
  6. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997;17:239–245
  7. National Institutes of Health. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  8. Huby T, Schroder W, Doucet C, et al. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. Biochemistry. 1995;34:7385–7393
  9. Beisiegel U, Niendorf A, Wolf K, et al. Lipoprotein(a) in the arterial wall. Eur Heart J. 1990;11:174–183
  10. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol. 1998;32:2035–2042
  11. Nielsen LB. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 1999;143:229–243
  12. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system?. Thromb Haemost. 1990;63:331–335
  13. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904–910
  14. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271–276
  15. Marcovina SM, Kennedy H, Bittolo Bon G, et al. Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: the Lugalawa Study. Arterioscler Thromb Vasc Biol. 1999;19:1250–1256
  16. Nelson GJ, Ackman RG. Absorption and transport of fat in mammals with emphasis on n-3 polyunsaturated fatty acids. Lipids. 1988;23:1005–1014
  17. Herrmann W, Biermann J, Kostner GM. Comparison of effects of n-3 to n-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol. 1995;76:459–462
  18. Haglund O, Mehta JL, Saldeen T. Effects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects. Am J Cardiol. 1994;74:189–192
  19. Beil FU, Terres W, Orgass M, et al. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. Atherosclerosis. 1991;90:95–97
  20. Eritsland J, Arnesen H, Berg K, et al. Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation. Scand J Clin Lab Invest. 1995;55:295–300
  21. Svensson M, Schmidt EB, Jorgensen KA, et al. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol Dial Transplant. 2008;23:2918–2924
  22. Jasti S, Siega-Riz AM, Cogswell ME, et al. Pill count adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr. 2005;135:1093–1101
  23. Lee JY, Kusek JW, Greene PG, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. 1996;9:719–725
  24. Grundt H, Nilsen DW, Hetland O, et al. Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr. 2004;23:491–500
  25. Wu WH, Lu SC, Wang TF, et al. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr. 2006;60:386–392
  26. Helland IB, Saugstad OD, Saarem K, et al. Supplementation of n-3 fatty acids during pregnancy and lactation reduces maternal plasma lipid levels and provides DHA to the infants. J Matern Fetal Neonatal Med. 2006;19:397–406
  27. Mostad IL, Bjerve KS, Lydersen S, et al. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr. 2008;62:419–429
  28. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384
  29. Rylance PB, Gordge MP, Saynor R, et al. Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients. Nephron. 1986;43:196–202
  30. Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37:2569–2585
  31. Barbagallo CM, Averna MR, Sparacino V, et al. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron. 1993;64:560–564
  32. Willett WC. The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. J Cardiovasc Med. 2007;8(Suppl):S42–S45
  33. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr. 2000;10:191–195
  34. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 1992;12:1214–1226
  35. Paultre F, Tuck CH, Boden-Albala B, et al. Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol. 2002;22:141–146
  36. Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE Study. Circulation. 2002;106:2812–2818
  37. Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. Clin Chem. 1994;40:574–578

PII: S1051-2276(09)00156-3

doi: 10.1053/j.jrn.2009.06.005

Journal of Renal Nutrition
Volume 19, Issue 6 , Pages 443-449 , November 2009

Article Tools